Tag Archives: Baxter

Short Attention Spin- Shire To Consider Spinning Off Neurological Division

By |
7 Comments

Shire Pharmaceuticals (SHPG) announced last week that it will be “assessing strategic options” for its Neuroscience franchise. The move would allow the company to focus its efforts on its rare diseases division. From the company’s Q2 statement: With the acquisition and integration of Baxalta, Shire has solidified its leadership position in rare diseases with an unparalleled inline portfolio, innovative… Read More »

After Swallowing Baxalta, Barron’s Sees 25% Upside For Shire

By |
6 Comments

Just months after being spun off from Baxter International(BAX), Baxalta found itself the target of an intense pursuit by Shire Pharmaceuticals(SHPG). Baxalta resisted, but, ultimately agreed to a deal which closed earlier this year. Barron’s sees good things ahead for the combined company. In an article this weekend, the venerable publication points out that merely by achieving a… Read More »

Baxalta Attempts To Bulk Up With Ariad To Avoid Shire Advances

By |
0 Comment

Just two months after its spinoff from Baxter International(BAX), as it continues to reject acquisition interest from Shire(SHPG), Baxalta(BXLT) is in talks to acquire Ariad Pharmaceuticals(ARIA). Ariad jumped 42% on the news last Friday, valuing the oncology company at nearly $2 billion. What is driving this potential acquisition? Is it the “Promise of the Baxalta Spark“?  Perhaps it’s… Read More »

Shire Makes A Move For Baxalta

By |
3 Comments

The Summer of Spin kicked off a little over one month ago, but already one of the spinoffs might be acquired. Shire(SHPG) unveiled an offer to acquire last month’s Baxter International (BAX) spinoff, Baxalta(BXLT).  According to the release, Shire contacted Baxalta in early July- immediately after the spinoff, met briefly on July 10, but Baxalta has not seriously considered… Read More »

I Know What You Spun This Summer: Summer Of Spin Day 3 Roundup and Looking Ahead

By |
0 Comment

What a week for spinoffs. Truly historic. Beginning on Monday with TEGNA (TGNA)/Gannett (GCI), the ‘Summer of Spin’ crescendoed yesterday with the completion of six more spins: DuPont (DD) spun off its performance chemicals unit (including Teflon) into Chemours (CC). The new company told investors it plans on paying out a stable dividend, which is somewhat unusual for such… Read More »

One Little Baxalta(BXLT) Spark Of Corporate Gobbledygook

By |
0 Comment

Baxalta(BXLT) completed its spinoff from Baxter International(BAX) yesterday. Or, as Baxalta would have it “Baxalta Launches as a Global Biopharmaceutical Leader Dedicated to Patients with Orphan Diseases and Underserved Conditions.”  Baxalta is no slouch, what with “New products and indications planned to contribute $2.5 billion in sales by 2020, building on base of $6 billion in annual revenue.”… Read More »

Summer Of Spin: Day 2 Roundup Featuring Baxalta And Friends

By |
0 Comment

The ‘Summer of Spin’ rolls on and yesterday witnessed the completion of three more spin offs: Masco (MAS) separated its installations and services into TopBuild (BLD) TriMas (TRS) spun off its former Cequent units as Horizon Global (HZN) Babcock & Wilcox (BWC) changed its name to BWX Technologies (BWXT) and spun off its power generation unit as Babcock &… Read More »

Baxalta Set To Enter S&P 500, Baxter Will leave S&P 100 On Completion Of Spinoff

By |
0 Comment

As previously discussed, Baxter International (BAX) will be spinning off Baxalta (BXLT) after the close of business on June 30. As is often the case with larger spinoffs this will result in some S&P index reshuffling. First, Baxter will no longer be large enough to remain a member of the S&P 100 and will be replaced by Priceline… Read More »

Baxter Set To Spin Off Baxalta on July 1

By |
0 Comment

You may never heard of Baxter International(BAX), but the $37 Billion behemoth may have saved your life. Now, the company is slimming down, as the Board has approved the July 1 spinoff of Baxalta(BXLT). Shareholders of record as of June 17 will receive one share of Baxalta for each Baxter share owned. Baxter will retain 19.5% of Baxalta… Read More »